Search clinical trials for: Surufatinib/Toripalimab

Total 453 results

The Affiliated Nanjing Drum Tower Hospital of Nanjing...
The First Affiliated Hospital with Nanjing Medical University; Fudan University and other collaborators

Not yet recruiting

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Pancreatic Carcinoma

China
Ruijin Hospital

Recruiting

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Advanced Cervical Cancer

China
Tao Zhang

Recruiting

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

Gastric Cancer Stage IV

China
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Peking University

Completed

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Advanced Biliary Tract Cancer

China
Guangzhou Institute of Respiratory Disease
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

China
RemeGen Co., Ltd.

Recruiting

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Breast Cancer

China
Henan Cancer Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Sun Yat-sen University

Not yet recruiting

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Penile Cancer
Beni-Suef University

Not yet recruiting

The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders

Poor Responders

Egypt
XIANG YANQUN

Recruiting

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | T2-3N0 or T1-2N1 | EBV-DNA≤4000 Copy/ml

China
Zhejiang Cancer Hospital

Recruiting

Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study

Gastric Adenocarcinoma

China
Fudan University

Recruiting

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Rectal Cancer

China
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China
First Affiliated Hospital of Guangxi Medical University
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Shandong... and other collaborators

Not yet recruiting

Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Chongqing University Cancer Hospital

Recruiting

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer (CQGOG0101)

Cervical Cancer

China
Eucure (Beijing) Biopharma Co., Ltd

Active, not recruiting

A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers

Melanoma | Pancreatic Ductal Adenocarcinoma

United States, Australia
Hao Long

Active, not recruiting

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer (NeoTAP01)

Non Small Cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Lung Diseases | Thoracic Neoplasms | Non-small Cell Lung Cancer | Pulmonary Sarcomatoid Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Mian XI

Completed

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Unresectable Esophageal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Melanoma | Urothelial Carcinoma | Renal Carcinoma

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Anti-PD1 Antibody

China
Fudan University

Recruiting

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E） (TORCH-E)

Early Low Rectal Cancer

China
Fudan University

Recruiting

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer (TORCH)

Locally Advanced Rectal Cancer

China
Second Affiliated Hospital, School of Medicine,...

Completed

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

High-Risk Resectable NSCLC

China
Sun Yat-sen University

Active, not recruiting

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. (NAJSCR)

Efficacy and Safety

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
Wei Ren

Recruiting

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital
Shanghai Junshi Bioscience Co., Ltd.

Suspended

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinoma

China
RemeGen Co., Ltd.

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
China Medical University, China

Recruiting

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Shengjing Hospital; Sun Yat-Sen Memorial Hospital of Sun... and other collaborators

Not yet recruiting

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 (TA7)

Gestational Trophoblastic Neoplasia

China
Jianhua Fu

Unknown

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Resectable Esophageal Cancer | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Healthy

United States
Xuhua Duan

Recruiting

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma

China
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Sun Yat-sen University

Active, not recruiting

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

DMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal Cancer

China
Xiangya Hospital of Central South University

Unknown

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma (Skin)

China
Second Affiliated Hospital, School of Medicine,...
Peking University People's Hospital; Qilu Hospital of Shandong University; Ruijin... and other collaborators

Not yet recruiting

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Osteosarcoma

China, Korea, Republic of
China Medical University, China

Not yet recruiting

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
First People's Hospital of Foshan

Not yet recruiting

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

China

3

Subscribe